Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70481 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von David Tornai und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Liver Cirrhosis, Microfilament Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Innovation and Technology of Hungary, Horizon 2020 Framework Programme, Ministry for Culture and Innovation of Hungary.
Abstract (Originalsprache)
Background
Gut barrier dysfunction contributes to acute decompensation (AD) of cirrhosis progression but, it is not acknowledged in severity or prognostic scores due to a lack of appropriate assessment tools.
Aim
We investigated serum villin‐1 (VIL1), an epithelial brush‐border associated actin‐binding protein, as a non‐invasive marker for gut injury and prognosis in AD cirrhosis.
Methods
Serum VIL1 was measured in 338 cirrhosis patients (discovery n = 130, validation n = 208, including acute‐on‐chronic liver failure [ACLF]) from MICROB‐PREDICT cohorts and 50 healthy controls (HC). Duodenal biopsies ( n = 49 patients, n = 11 HC) were assessed for tissue VIL1 via immunohistochemistry. Serum cytokine profiling linked serum VIL1 levels to systemic inflammation.
Results
Compared to HC, both serum and tissue VIL1 levels were lower in stable AD patients. However, serum VIL1 progressively increased with AD severity, peaking in ACLF. Serum VIL1 was associated with 90‐day mortality (AUROC: 0.721, p < 0.001; similar to MELD: 0.722, p < 0.001). A cut‐off > 12.79 ng/mL enhanced the prognostic accuracy provided by severe disease stage, defined as CLIF‐C AD score ≥ 50 or ACLF (low VIL1: 17.5% vs. high VIL1: 53.6% mortality). This threshold was associated with increased systemic inflammation, suggesting enhanced bacterial translocation. VIL1 was an independent predictor of 90‐day mortality (HR: 2.52, CI: 1.648–3.848, p < 0.001) in Cox regression. All findings were confirmed in the validation cohort.
Conclusion
Serum VIL1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in AD cirrhosis. Incorporating VIL1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Kalman Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
ORCID-Profile: David Tornai, Richard Moreau, Jonel Trebicka, Maria Papp
Förderung
- Ministry of Innovation and Technology of Hungary
- Horizon 2020 Framework Programme
- Ministry for Culture and Innovation of Hungary
- Magyar Tudományos Akadémia
Zitieren
APA
Tornai, D., Balogh, B., Csillag, A., Budai, A., Kiss, A., Antal-Szalmas, P., Mehes, G., Barath, L., Tornai, T., Tornai, I., Vitalis, Z., Sipeki, N., Dinya, T., Enyedi, A., Rosenberger, F. A., Laleman, W., Coenraad, M. J., Aguilar, F., Claria, J., …, & MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium (2025). Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70481
Vancouver
Tornai D, Balogh B, Csillag A, Budai A, Kiss A, Antal-Szalmas P, et al. Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70481
BibTeX
@article{Tornai2025,
author = {Tornai, David and Balogh, Boglarka and Csillag, Aniko and Budai, Andras and Kiss, Andras and Antal-Szalmas, Peter and Mehes, Gabor and Barath, Lukacs and Tornai, Tamas and Tornai, Istvan and Vitalis, Zsuzsanna and Sipeki, Nora and Dinya, Tamas and Enyedi, Attila and Rosenberger, Florian A and Laleman, Wim and Coenraad, Minneke J and Aguilar, Ferran and Claria, Joan and Moreau, Richard and Trebicka, Jonel and Papp, Maria and MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium, MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium},
title = {Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70481}
}
EUVIMED